Pfizer Sees Future Deals as China Biopharma Consolidates

To increase dealmaking in China, Pfizer has built a Shanghai-based business development team. On the one hand, the mega-pharma is looking forward to revenue growth in the China pharma market, while on the other hand it expects China’s famously fragmented pharmaceutical industry to begin a long-awaiting process of consolidation. For both reasons, China figures large in the company’s development plans for the next three to five years. More details... Stock Symbol: (NYSE: PFE)